Breaking News

Catalent, Adamas Enter CTM Agreement

By Kristin Brooks | January 8, 2014

Catalent to manufacture ADS-5102 for Phase III trials

Catalent Pharma Solutions and Adamas Pharmaceuticals have entered an agreement for the manufacture of ADS-5102 (amantadine HCl) extended release capsules for Phase III trials. ADS-5102 is an investigational drug being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.
 
“We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, Ph.D., Adamas chairman and chief executive officer.
 
Barry Littlejohns, president of Catalent’s Advanced Delivery Technologies business, said, “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments. We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials